Your browser doesn't support javascript.
loading
Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors.
Chen, Eddy J; Sowalsky, Adam G; Gao, Shuai; Cai, Changmeng; Voznesensky, Olga; Schaefer, Rachel; Loda, Massimo; True, Lawrence D; Ye, Huihui; Troncoso, Patricia; Lis, Rosina L; Kantoff, Philip W; Montgomery, Robert B; Nelson, Peter S; Bubley, Glenn J; Balk, Steven P; Taplin, Mary-Ellen.
Afiliação
  • Chen EJ; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
  • Sowalsky AG; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
  • Gao S; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
  • Cai C; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
  • Voznesensky O; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
  • Schaefer R; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
  • Loda M; Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • True LD; University of Washington, Seattle, Washington.
  • Ye H; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
  • Troncoso P; University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Lis RL; Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Kantoff PW; Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Montgomery RB; University of Washington, Seattle, Washington.
  • Nelson PS; University of Washington, Seattle, Washington. Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Bubley GJ; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
  • Balk SP; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts. sbalk@bidmc.harvard.edu mary_taplin@dfci.harvard.edu.
  • Taplin ME; Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. sbalk@bidmc.harvard.edu mary_taplin@dfci.harvard.edu.
Clin Cancer Res ; 21(6): 1273-80, 2015 Mar 15.
Article em En | MEDLINE | ID: mdl-25320358
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Prostata Base de dados: MEDLINE Assunto principal: Progesterona / Esteroide 17-alfa-Hidroxilase / Receptores Androgênicos / Neoplasias de Próstata Resistentes à Castração / Androstenos Tipo de estudo: Prognostic_studies Limite: Aged / Aged80 / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2015 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Prostata Base de dados: MEDLINE Assunto principal: Progesterona / Esteroide 17-alfa-Hidroxilase / Receptores Androgênicos / Neoplasias de Próstata Resistentes à Castração / Androstenos Tipo de estudo: Prognostic_studies Limite: Aged / Aged80 / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2015 Tipo de documento: Article